INCHEON, Korea ? June 30, 2020?? Samsung Bioepis Co., Ltd. today announced the initiation of Phase 3 clinical trial for SB15, the company's proposed biosimilar referencing Eylea^?? (aflibercept). The Phase 3 clinical trial for SB15 (aflibercept) is a randomised, double-masked, parallel group, multicenter study to compare the efficacy, safety, pharmacokinetics, and immunogenicity between SB15 and Eylea^??in 446 patients with neovascular age-related macular degeneration. For more information, please visit?clinicaltrials.gov?(NCT #04450329). Samsung Bioepis has two ophthalmology biosimilar candidates in clinical development, SB11 (ranibizumab) and SB15 (aflibercept). The company has recently announced 24-week interim results from a Phase 3 clinical trial for SB11.

# # #

About Samsung Bioepis Co., Ltd. Established in 2012, Samsung Bioepis is a biopharmaceutical company committed to realizing healthcare that is accessible to everyone. Through innovations in product development and a firm commitment to quality, Samsung Bioepis aims to become the world's leading biopharmaceutical company. Samsung Bioepis continues to advance a broad pipeline of biosimilar candidates that cover a spectrum of therapeutic areas, including immunology, oncology, ophthalmology and hematology. Samsung Bioepis is a joint venture between Samsung BioLogics and Biogen. For more information, please visit:?www.samsungbioepis.com?and follow us on social media??Twitter,?LinkedIn. MEDIA CONTACT Evelyn Hong: +82-31-8061-1215,?eubene.hong@samsung.com Anna Nayun Kim: +82-31-8061-1604,?nayun86.kim@samsung.com Yoon Kim: +82-31-8061-1783,?yoon1.kim@samsung.com ^i?Eylea^??is a registered trademark of Regeneron Pharmaceuticals